Modality
Peptide
MOA
BiTE
Target
APOC3
Pathway
Tau
SCLCIgAN
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
~Jan 2017
→ ~Apr 2018
Phase 2
Jul 2018
→ Sep 2030
Phase 2Current
NCT04559471
491 pts·SCLC
2020-06→2030-09·Terminated
NCT07395879
2,735 pts·IgAN
2018-07→2026-07·Active
3,226 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-07-013mo awayPh3 Readout· IgAN
2030-09-114.4y awayPh3 Readout· SCLC
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Active
P2/3
Termina…
Catalysts
Ph3 Readout
2026-07-01 · 3mo away
IgAN
Ph3 Readout
2030-09-11 · 4.4y away
SCLC
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04559471 | Phase 2/3 | SCLC | Terminated | 491 | NT-proBNP |
| NCT07395879 | Phase 2/3 | IgAN | Active | 2735 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| BII-8315 | Biogen | NDA/BLA | CDK2 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Talasotorasib | Exelixis | Preclinical | APOC3 |